2022 Guide to Patient Support Services

Heron Therapeutics

Heron Connect Patient Support Services

844-437-6611

Heron Therapeutics offers the Heron Connect patient support program to provide appropriate information and assistance to patients who have been prescribed Cinvanti or Sustol (Table).

Heron Connect

Heron Connect Patient Assistance Program

To receive Cinvanti or Sustol free of cost, patients must:

  • Be using Cinvanti or Sustol as prescribed
  • Be uninsured or have limited drug coverage
  • Have noncommercial insurance, but be determined as uninsured after first level of appeal is denied for the initial treatment
  • Have an annual income equal to or less than 500% of the federal poverty level
  • Be a resident of the United States or its territories
  • Receive treatment in an outpatient setting.

Program eligibility is for 12 months, after which the patient will need to reapply for continued assistance.

Heron Commitment Program

Heron Therapeutics is dedicated to ensuring patients and providers have access to Cinvanti and/or Sustol. The Heron Commitment Program helps mitigate the economic burden of denials. To qualify, commercially insured patients with confirmed medication coverage before drug administration with claims denials must have met the following documented criteria:

  • Prior authorization and verification of benefits meet all the payer criteria and/or policy requirements
  • Submitted claim is denied by the commercial payer
  • Claim is denied again after the first level of appeals process.

For more information about patient assistance options, call Heron Connect at 844-437-6611.

TABLE Heron Therapeutics Oncology Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Cinvanti (aprepitant) injectable emulsion
Indications
Patient support programs

Drug
Sustol (granisetron) extended-release injection
Indications
In combination with other antiemetic agents in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of MEC or anthracycline and cyclophosphamide combination chemotherapy regimens
Patient support programs

HEC indicates highly emetogenic chemotherapy; MEC, moderately emetogenic chemotherapy.

Cinvanti (aprepitant) injectable emulsion Indications

In combination with other antiemetic agents, is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of HEC, including high-dose cisplatin as a single-dose regimen; delayed nausea and vomiting associated with initial and repeat courses of MEC as a single-dose regimen; nausea and vomiting associated with initial and repeat courses of MEC as a 3-day regimen

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)